Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URT039
MIFTS: 58

Urticaria

Categories: Immune diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Urticaria

About this section

MalaCards integrated aliases for Urticaria:

Name: Urticaria 12 74 29 54 6 15 17 71 32

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1555
ICD9CM 34 708.8
ICD10 32 L50 L50.2 L50.9
UMLS 71 C0029839 C0042109
Sources

Summaries for Urticaria

About this section
Disease Ontology : 12 A skin disease characterized by skin rash notable for pale red, raised and itchy bumps, located in the upper dermis.

MalaCards based summary : Urticaria is related to cold urticaria and physical urticaria, and has symptoms including fatigue, fever and edema. An important gene associated with Urticaria is F12 (Coagulation Factor XII), and among its related pathways/superpathways are NF-kappaB Signaling and Development VEGF signaling via VEGFR2 - generic cascades. The drugs leucovorin and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include upper dermis, skin and testes, and related phenotype is immune system.

Wikipedia : 74 Hives, also known as urticaria, is a kind of skin rash with red, raised, itchy bumps. They may also burn... more...

Sources

Related Diseases for Urticaria

About this section

Diseases in the Urticaria family:

Rare Urticaria

Diseases related to Urticaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 689)
# Related Disease Score Top Affiliating Genes
1 cold urticaria 34.6 RNASE3 PLCG2 NLRP3 CMA1
2 physical urticaria 34.6 TPT1 NLRP3 HRH1 ADGRE2
3 dermographism, familial 33.5 PRG2 IGHE
4 paragonimiasis 32.1 RNASE3 IGHE
5 angioedema 31.7 PTGS2 PTGS1 LTC4S IGHE HRH1 HNMT
6 hereditary angioedema 31.0 F12 CPN1 C1S
7 conjunctivitis 30.9 RNASE3 NLRP3 IGHE HRH1
8 autoinflammatory syndrome 30.9 PLCG2 NLRP3
9 anisakiasis 30.9 RNASE3 IGHE
10 toxocariasis 30.8 RNASE3 IGHE
11 pollen allergy 30.6 RNASE3 PRG2 IGHE
12 hypereosinophilic syndrome 30.6 RNASE3 PRG2 IGHE
13 wells syndrome 30.5 RNASE3 NLRP3
14 gastrointestinal ulceration, recurrent, with dysfunctional platelets 30.4 PTGS2 PTGS1
15 c1 inhibitor deficiency 30.3 F12 C1S
16 food allergy 30.3 TPT1 RNASE3 IGHE HRH1 FCER2 AOC1
17 allergic rhinitis 30.2 TPT1 SELE RNASE3 IGHE HRH1 HNMT
18 allergic hypersensitivity disease 30.2 TPT1 SELE RNASE3 IGHE HRH1 FCER2
19 rhinitis 30.1 TPT1 RNASE3 PTGS1 PRG2 IGHE HRH1
20 allergic conjunctivitis 30.1 RNASE3 IGHE HRH1
21 bullous pemphigoid 30.0 RNASE3 IGHE FCER2
22 dermatitis, atopic 30.0 SELE RNASE3 PRG2 IGHE HRH1 FCER2
23 hydrops, lactic acidosis, and sideroblastic anemia 30.0 PTGS2 PTGS1 C1S
24 active peptic ulcer disease 30.0 PTGS2 PTGS1
25 proteasome-associated autoinflammatory syndrome 1 29.9 SELE RNASE3 PTGS2 PTGS1 NLRP3
26 malaria 29.4 TPT1 SELE RNASE3 PTGS2 PTGS1 NLRP3
27 asthma 28.5 TPT1 SELE RNASE3 PTGS1 PRG2 NLRP3
28 vibratory urticaria 12.9
29 cholinergic urticaria 12.7
30 solar urticaria 12.7
31 allergic urticaria 12.7
32 urticaria, aquagenic 12.7
33 papular urticaria 12.5
34 familial cold autoinflammatory syndrome 3 12.4
35 schnitzler syndrome 12.3
36 mastocytosis, cutaneous 12.3
37 familial cold autoinflammatory syndrome 1 12.3
38 muckle-wells syndrome 12.3
39 dermatographia 12.3
40 familial cold autoinflammatory syndrome 12.2
41 nodular urticaria pigmentosa 12.2
42 urticaria, familial localized heat 12.2
43 genetic urticaria 12.1
44 plaque-form urticaria pigmentosa 12.1
45 typical urticaria pigmentosa 12.1
46 rare urticaria 12.1
47 familial cold autoinflammatory syndrome 4 11.9
48 systemic mastocytosis 11.5
49 exercise-induced anaphylaxis 11.5
50 cryopyrin-associated periodic syndrome 11.4

Comorbidity relations with Urticaria via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential

Graphical network of the top 20 diseases related to Urticaria:



Diseases related to Urticaria
Sources

Symptoms & Phenotypes for Urticaria

About this section

UMLS symptoms related to Urticaria:


fatigue, fever, edema, pruritus, nausea and vomiting, abdominal pain, chest pain, constipation, headache, syncope, diarrhea, pain, chronic pain, sciatica, halitosis, icterus, exanthema, coughing, vertigo/dizziness, symptoms, dyspepsia, heartburn, gastrointestinal gas, pelvic pain, welts, darier's sign

MGI Mouse Phenotypes related to Urticaria:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.36 CMA1 CPN1 FCER2 HRH1 LTC4S NLRP3
Sources

Drugs & Therapeutics for Urticaria

About this section

Drugs for Urticaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 232)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4 58-05-9 6006 143
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
4
Hydroxyzine Approved Phase 4 68-88-2 3658
5
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
6
Ebastine Approved, Investigational Phase 4 90729-43-4 3191
7 Benralizumab Approved, Investigational Phase 4 1044511-01-4
8
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
9
Clevidipine Approved, Investigational Phase 4 167221-71-8
10
Cefpirome Approved Phase 4 84957-29-9 5479539
11
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
12
Azithromycin Approved Phase 4 83905-01-5 447043 55185
13
Praziquantel Approved, Investigational, Vet_approved Phase 4 55268-74-1 4891
14
Cefazolin Approved Phase 4 25953-19-9 656510 33255
15
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
16
Tranexamic Acid Approved Phase 4 1197-18-8 5526
17
Levocetirizine Approved Phase 4 130018-77-8 1549000
18
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
19
Cetirizine Approved Phase 4 83881-51-0 2678
20
Histamine Approved, Investigational Phase 4 51-45-6 774
21
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
23 Vitamin B Complex Phase 4
24 Folic Acid Antagonists Phase 4
25 Folate Phase 4
26 Vitamin B9 Phase 4
27 Antiprotozoal Agents Phase 4
28 Antimalarials Phase 4
29 Antimetabolites Phase 4
30 Anti-Infective Agents Phase 4
31 Antiparasitic Agents Phase 4
32 Anti-Bacterial Agents Phase 4
33 Norgestimate, ethinyl estradiol drug combination Phase 4
34 calcium channel blockers Phase 4
35 Antibiotics, Antitubercular Phase 4
36 Clindamycin phosphate Phase 4
37 Clindamycin palmitate Phase 4
38 Anthelmintics Phase 4
39 penicillins Phase 4
40 Hypolipidemic Agents Phase 4
41 Lipid Regulating Agents Phase 4
42 Hemostatics Phase 4
43 Antifibrinolytic Agents Phase 4
44 Coagulants Phase 4
45 Adrenergic beta-Antagonists Phase 4
46 Adrenergic Agents Phase 4
47 Adrenergic Antagonists Phase 4
48 Sodium Channel Blockers Phase 4
49 Sympatholytics Phase 4
50 Anti-Arrhythmia Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 268)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of Desloratadine 5mg (Denosin®) With Levocetirizine 5mg (Xyzal®) in the Treatment of Chronic Idiopathic Urticaria Patients Unknown status NCT00346606 Phase 4 Denosin® and Xyzal®
2 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
3 mRNA Expression as a Biomarker of Xolair (Omalizumab) Response Unknown status NCT01584687 Phase 4
4 A Phase IV, Multicenter, Single-arm and Open-label Study With Omalizumab (Xolair®) in Chronic Spontaneous Urticaria (CSU) Patients Who Remain Symptomatic Despite Antihistamine (H1) Treatment Completed NCT02550106 Phase 4 OMALIZUMAB
5 A Comparative Study on Clinical Efficacy and Safety of Levocetirizine 5 mg Oral Capsules Once Daily in the Morning vs. Desloratadine 5 mg Oral Capsules Once Daily in the Morning in Patients Suffering From Chronic Idiopathic Urticaria (CIU) Completed NCT00264303 Phase 4 Levocetirizine;Desloratadine
6 Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria Completed NCT01701583 Phase 4 Omalizumab
7 Multi-center, Double Blind, Dose Escalating Study to Compare the Effects of 5 mg, 10mg and 20mg of Desloratadine in Patients With Acquired Cold Urticaria (ACU) Completed NCT01444196 Phase 4 Desloratadine
8 An Exploratory Phase IV, Randomised, Double-Blind, Placebo Controlled Crossover Study to Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Experimentally Induced Urticaria Lesions Completed NCT00600847 Phase 4 desloratadine;desloratadine;placebo
9 An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria Completed NCT00795522 Phase 4 Desloratadine
10 XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria Completed NCT02392624 Phase 4 Omalizumab;Placebo
11 A Study of the Efficacy, Safety, and Quality of Life (QOL) in Patients With Chronic Idiopathic Urticaria Dosed With AERIUS Tablets (Desloratadine 5 mg, 10 mg, or 20 mg Once Daily) Completed NCT00536380 Phase 4 5-mg Desloratadine;10-mg Desloratadine;20-mg Desloratadine
12 A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU) Completed NCT00751218 Phase 4 desloratadine;placebo;cetirizine
13 A Pilot, Multicenter, Double-blind Randomized Study for Comparison of Aerius® "Continuous Treatment" Versus Aerius® "PRN Regimen" on Chronic Idiopathic Urticaria Patient Quality of Life Completed NCT00783354 Phase 4 desloratadine;desloratadine
14 Efficacy and Safety of 20 mg Levocetirizine and 15 mg Levocetirizine + 50 mg Bed-Time Hydroxyzine in Severe Chronic Urticaria in Adults: a Pilot, Randomized, Double-blind, Cross-over and Parallel, Active-controlled, Single-centre Study Completed NCT01250652 Phase 4 Levocetirizine;Levocetirizine plus Hydroxyzine
15 Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria Completed NCT01940393 Phase 4 Cetirizine;Desloratadine;Fexofenadine;Ebastine;Bilastine
16 Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monocloncal Antibody Completed NCT03183024 Phase 4
17 Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria Completed NCT02576041 Phase 4 Bilastine;Placebo
18 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria Completed NCT03111628 Phase 4 Omalizumab
19 Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response Completed NCT01586091 Phase 4 Levocetirizine Oral Tablet;Fexofenadine 60 Mg Oral Tablet;Placebo Oral Tablet
20 Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed (CARVE) Completed NCT01121458 Phase 4 Clevidipine
21 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
22 A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation Completed NCT01915082 Phase 4 Azithromycin;Ora-Plus
23 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
24 Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Completed NCT01244698 Phase 4 Cefadroxil discontinued early;Cefadroxil until drain removal
25 Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction Completed NCT02291796 Phase 4 Bezafibrate
26 Efficacy and Safety of Levocetirizine Alone or in Combination With Tranexamic Acid in the Treatment of Spontaneous Chronic Urticaria. Multicentric Controlled Randomized Study in Cross-over, Double-blind Recruiting NCT03789422 Phase 4 association of levocetirizine and tranexamic acid;Levocetirizine only
27 A Randomised Controlled Trial to Evaluate the Effect of Vitamin D Supplementation in Patients With Chronic Urticaria Enrolling by invitation NCT03991845 Phase 4 Vit D
28 A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Not yet recruiting NCT02347111 Phase 4 Flecainide;Sotalol
29 Comparison of Timing and Image Quality of Different Phases of Optos Fluorescein Angiography Between Two Doses of Intravenous Fluorescein: 250mg Versus 500mg Suspended NCT03244982 Phase 4 Fluorescein Na 10% Inj 500mg;Fluorescein Na 10% Inj 250mg
30 A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU) Terminated NCT00751166 Phase 4 Desloratadine;Cetirizine;placebo
31 Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation Withdrawn NCT02742805 Phase 4 Omalizumab
32 High Dose Vitamin D Supplementation in Treatment of Chronic Spontaneous Urticaria Unknown status NCT02873364 Phase 3 Vitamin D3 (High dose);Vitamin D3 (Low dose)
33 Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria Unknown status NCT02166151 Phase 3 Omalizimab
34 Intravenous Versus Oral Regimens of Dexamethasone for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction in Primary Ovarian, Fallopian Tube and Peritoneal Cancer Patients: a Double-blind Randomized Controlled Trial Unknown status NCT02349763 Phase 3 Intravenous Dexamethasone;Oral Dexamethasone
35 A Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Chronic Idiopathic Urticaria (CIU) Completed NCT00525382 Phase 3 levocetirizine dihydrochloride
36 Multicenter Pilot Phase III Clinical Trials of JDP-205 iv Injection for the Treatment of Acute Urticaria Associated With an Acute Allergic Reaction. Completed NCT02023164 Phase 3 JDP-205 Injection;Diphenhydramine
37 Glucocorticoids Associated With Antihistamines Versus Antihistamines Randomized Double Blinded for the Management of Acute Urticaria in Emergency Completed NCT02565680 Phase 2, Phase 3 placebo;prednisone
38 An Exploratory Phase III, Randomised, Double-blind, Therapeutic Single Dose-related Effect, Parallel Group Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU) Completed NCT00598611 Phase 3 desloratadine;desloratadine
39 A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria. Completed NCT01916967 Phase 3 Desloratadine;Placebo
40 Phase 3 Study, Exploratory, Disease Activity Controlled Dose Escalating Study to Assess the Efficacy, and Safety of Treatment With Bilastine 20 mg, 40 mg and 80 mg in Chronic Spontaneous Urticaria. Completed NCT02213367 Phase 3 Bilastine;Bilastine;Bilastin
41 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With Symptoms of Allergic Rhinitis or Chronic Urticaria. Completed NCT00628108 Phase 3 Levocetirizine 1.25 mg
42 Randomized Clinical Trial Evaluating the Efficacy of Methotrexate in Addition to Anti-H1 Versus Placebo and Anti-H1 in the Treatment of Severe Chronic Idiopathic Urticaria Completed NCT01960283 Phase 3 Methotrexate (Novatrex ®) + anti-H1;Placebo + anti-H1
43 Study of the Effects of Antipruritic Chinese Herbal Medicine on Chronic Urticaria: a Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial. Completed NCT01715740 Phase 3 Chinese Herbal Medicine (CHM);Placebo
44 Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria Completed NCT00421109 Phase 3 Bilastine;Levocetirizine;Placebo
45 A Randomized, Double-blind, Placebo-controlled, 28-week Treatment With a 8 Week Follow-up to Investigate the Impact of Omalizumab on Quality of Life Measures and the Incidence and Severity of Angioedema Despite H1-antihistamine Therapy. Completed NCT01723072 Phase 3 Placebo
46 An Open-Label Study of the Effects of Desloratadine Treatment on the Quality of Life of Patients With Chronic Urticaria Completed NCT00795158 Phase 3 desloratadine
47 Multiple-Dose Safety and Tolerance Study of Desloratadine in Atopic Pediatric Subjects and Pediatric Subjects With Chronic Idiopathic Urticaria, Ages >=2 to <12 Years, Who Are Poor Metabolizers of Desloratadine Completed NCT00757562 Phase 3 desloratadine;Placebo
48 A Multi-Center, Randomized, Double Blind, Placebo Controlled Parallel Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d Dosing in Children Aged 1 to < 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin Completed NCT00619801 Phase 3 Levocetirizine;Placebo
49 Double-blind, Triple Cross-over, Placebo-controlled Study to Assess the Efficacy, Mechanisms, and Safety of Treatment With Bilastine 20 mg, 40 mg and 80 mg in Cold Contact Urticaria (CCU) Completed NCT01271075 Phase 2, Phase 3 Bilastine;Bilastine
50 Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria Resistant to the Licensed Dosage Completed NCT02372604 Phase 3 Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.;Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.

Search NIH Clinical Center for Urticaria

Inferred drug relations via UMLS 71 / NDF-RT 50 :


acrivastine
Astemizole
azatadine
Azatadine maleate
bromodiphenhydramine
Bromodiphenhydramine hydrochloride
Cetirizine
cetirizine hydrochloride
Chlorpheniramine
Chlorpheniramine Maleate
CHLORPHENIRAMINE POLISTIREX
Chlorpheniramine Tannate
Cimetidine
Cimetidine Hydrochloride
Clemastine
Clemastine Fumarate
Cyproheptadine
Cyproheptadine hydrochloride
CYPROHEPTADINE HYDROCHLORIDE MONOHYDRATE
desloratadine
dexchlorpheniramine
Dexchlorpheniramine maleate
Diphenhydramine
Diphenhydramine Citrate
Diphenhydramine Hydrochloride
Famotidine
fexofenadine
Fexofenadine hydrochloride
levocetirizine
levocetirizine dihydrochloride
Loratadine
methdilazine
Methdilazine hydrochloride
Nizatidine
phenindamine
Phenindamine tartrate
Pheniramine
Pheniramine Maleate
phenyltoloxamine
Phenyltoloxamine citrate
PHENYLTOLOXAMINE RESIN COMPLEX
Trimeprazine
trimeprazine tartrate
Tripelennamine
Tripelennamine citrate
Tripelennamine Hydrochloride
Sources

Genetic Tests for Urticaria

About this section

Genetic tests related to Urticaria:

# Genetic test Affiliating Genes
1 Urticaria (disease) 29
Sources

Anatomical Context for Urticaria

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Urticaria:

19
Upper Dermis

MalaCards organs/tissues related to Urticaria:

40
Skin, Testes, Thyroid, Neutrophil, Bone, T Cells, Liver
Sources

Publications for Urticaria

About this section

Articles related to Urticaria:

(show top 50) (show all 13750)
# Title Authors PMID Year
1
Increased total and mite-specific immunoglobulin E in patients with aspirin-induced urticaria and angioedema. 61 54
20461968 2010
2
Paradoxical exacerbation of chronic urticaria by H1-antihistamines and montelukast. 54 61
20128233 2009
3
Association of acute urticaria with Mycoplasma pneumoniae infection in hospitalized children. 54 61
19739426 2009
4
Simultaneous occurrence of chronic autoimmune urticaria and non-allergic asthma: a common mechanism? 54 61
19585861 2009
5
Comparison of the in vivo autologous skin test with in vitro diagnostic tests for diagnosis of chronic autoimmune urticaria. 54 61
19026096 2009
6
The A-444C polymorphism in the leukotriene C4 synthase gene is associated with aspirin-induced urticaria. 54 61
19862937 2009
7
Differential diagnosis of chronic urticaria. 61 54
18426134 2008
8
[Angioedema]. 54 61
18004529 2007
9
Safety of celecoxib in patients with cutaneous reactions due to ASA-NSAIDs intolerance. 61 54
17663920 2007
10
Natural rubber latex sensitisation and allergy in patients with spina bifida, urogenital disorders and oesophageal atresia compared with a normal paediatric population. 61 54
17638159 2007
11
Histamine and histamine intolerance. 61 54
17490952 2007
12
Safety of selective cyclooxygenase-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema: Comparison of meloxicam, etodolac and tiaramide. 61 54
17291297 2007
13
Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. 61 54
17902729 2007
14
Cellular adhesion molecules in chronic urticaria: modulation of serum levels occurs during levocetirizine treatment. 61 54
17107400 2006
15
Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria. 54 61
16937749 2006
16
Genetic mechanism of aspirin-induced urticaria/angioedema. 61 54
16825866 2006
17
Cellular infiltrate and related cytokines, chemokines, chemokine receptors and adhesion molecules in chronic autoimmune urticaria: comparison between spontaneous and autologous serum skin test induced wheal. 54 61
17026835 2006
18
Patients with papular urticaria have IgG antibodies to bedbug (Cimex lectularius) antigens. 54 61
16425065 2006
19
An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL). 54 61
16505276 2006
20
Monoclonal gammopathy in association with allergic disorders of the skin and respiratory tract. 54 61
16724632 2006
21
HLA-DRB genotype and specific IgE responses in patients with allergies to penicillins. 54 61
16584643 2006
22
Pathophysiology of urticaria. 61 54
16461989 2006
23
Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant. 54 61
16433794 2006
24
Eosinophil cationic protein in patients with fascioliasis: its probable effects on symptoms and signs. 61 54
16709536 2006
25
Angioedema. 61 54
16112343 2005
26
Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. 54 61
16136765 2005
27
Identification of IgE-binding epitopes on gliadins for patients with food allergy to wheat. 54 61
15876313 2005
28
Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli. 61 54
15836753 2005
29
COX-2 selective nonsteroidal anti-inflammatory drugs: current status. 54 61
15926604 2005
30
No evidence of increased serum substance P levels in chronic urticaria patients with and without demonstrable circulating vasoactive factors. 61 54
15725248 2005
31
Aspirin sensitivity: implications for patients with coronary artery disease. 54 61
15613671 2004
32
Drug-induced urticaria. 61 54
15335302 2004
33
Aspirin and NSAID sensitivity. 54 61
15242723 2004
34
Periodic fever, mild arthralgias, and reversible moderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients--expanding phenotype of CIAS1 related autoinflammatory syndrome. 61 54
15245511 2004
35
Immune and histopathologic examination of flea bite-induced papular urticaria. 61 54
15104197 2004
36
Protein sequence analysis of a novel 103-kDa Dermatophagoides pteronyssinus mite allergen and prevalence of serum immunoglobulin E reactivity to rDer p 11 in allergic adult patients. 61 54
15005727 2004
37
Chronic urticaria: aetiology, management and current and future treatment options. 61 54
15516152 2004
38
Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. 54 61
14676074 2003
39
[A potential of positron emission tomography in the drug development of non-sedative antihistamines]. 61 54
14727529 2003
40
Exogenous oestrogen as an alternative to food allergy in the aetiology of angioneurotic oedema. 61 54
12505453 2003
41
Increased circulating FcepsilonRII-bearing B-lymphocytes and serum levels of IL-4 in non-autoreactive chronic idiopathic urticaria. 54 61
15719607 2003
42
Characterization of asparagus allergens: a relevant role of lipid transfer proteins. 54 61
12417890 2002
43
Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: a double-blind, placebo-controlled study versus loratadine. 61 54
12269652 2002
44
[Autoantibodies to thyroid gland antigens in chronic relapsing urticaria]. 54 61
12525007 2002
45
Milk-induced urticaria is associated with the expansion of T cells expressing cutaneous lymphocyte antigen. 61 54
11941320 2002
46
Urticaria and angioedema induced by COX-2 inhibitors. 61 54
11842312 2002
47
Hereditary angioedema as a cause of transient abdominal pain. 61 54
11743247 2002
48
NSAID-induced urticaria and angioedema: a reappraisal of its clinical management. 61 54
12444802 2002
49
Urticaria and angioedema from cyclooxygenase-2 inhibitors. 54 61
11708434 2001
50
Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. 61 54
11570615 2001
Sources

Variations for Urticaria

About this section

ClinVar genetic disease variations for Urticaria:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 F12 NM_000505.3(F12):c.983C>G (p.Thr328Arg)SNV Pathogenic 1170 rs118204456 5:176831232-176831232 5:177404231-177404231
2 MEFV NM_000243.3(MEFV):c.2084A>G (p.Lys695Arg)SNV Conflicting interpretations of pathogenicity 2547 rs104895094 16:3293403-3293403 16:3243403-3243403
Sources

Expression for Urticaria

About this section
Search GEO for disease gene expression data for Urticaria.
Sources

Pathways for Urticaria

About this section

Pathways related to Urticaria according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
NF-kappaB Signaling 4
12.18 TPT1 PTGS2 PTGS1 PLCG2
2
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 11.64 SELE PTGS2 PTGS1 PLCG2
3
Linoleic acid metabolism 36
Show member pathways
 11.57 PTGS2 PTGS1 LTC4S
4
Interleukin-4 and 13 signaling 65
11.49 PTGS2 IGHE FCER2
5
Prostaglandin 2 biosynthesis and metabolism FM 22
10.79 PTGS2 PTGS1
6
Overview of nanoparticle effects 1
10.68 PTGS2 PTGS1
7
Etoposide Pathway, Pharmacokinetics/Pharmacodynamics 60
10.33 PTGS2 PTGS1
8
Eicosanoid Synthesis 1
10.18 PTGS2 PTGS1 LTC4S
Sources

GO Terms for Urticaria

About this section

Cellular components related to Urticaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.76 TPT1 PTGS1 PRG2 PLCG2 HNMT FCER2
2 extracellular space GO:0005615 9.56 TPT1 SELE RNASE3 F12 CPN1 CMA1
3 extracellular region GO:0005576 9.32 RNASE3 PRG2 NLRP3 IGHE FCER2 F12

Biological processes related to Urticaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.85 RNASE3 NLRP3 IGHE F12 C1S
2 cellular oxidant detoxification GO:0098869 9.5 PTGS2 PTGS1 LTC4S
3 prostaglandin biosynthetic process GO:0001516 9.48 PTGS2 PTGS1
4 lipoxygenase pathway GO:0019372 9.43 PTGS2 LTC4S
5 response to glucocorticoid GO:0051384 9.43 PTGS2 HNMT CPN1
6 peptide metabolic process GO:0006518 9.4 CPN1 CMA1
7 cyclooxygenase pathway GO:0019371 9.37 PTGS2 PTGS1
8 regulation of inflammatory response GO:0050727 9.26 SELE PTGS2 NLRP3 CMA1
9 cellular response to histamine GO:0071420 9.16 HRH1 AOC1
10 inflammatory response GO:0006954 9.1 SELE PTGS2 PTGS1 NLRP3 HRH1 ADGRE2

Molecular functions related to Urticaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS2 PTGS1
Sources

Sources for Urticaria

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....